癌症治疗期间内分泌治疗所致骨丢失的管理
本文为叙述性综述,总结激素受体阳性早期乳腺癌及非转移性前列腺癌患者在内分泌治疗期间癌症治疗所致骨丢失的管理文献。骨折风险评估工具(FRAX)可指导骨质疏松治疗;对化疗诱导卵巢衰竭、卵巢切除术、促性腺激素释放激素治疗、芳香化酶抑制剂治疗及雄激素剥夺治疗患者,骨改良药物应在高于FRAX推荐阈值的T值启动;骨合成代谢药物序贯治疗可能为高即刻骨折风险患者提供治疗策略。
要点
- 骨改良药物用于治疗激素受体阳性早期乳腺癌和非转移性前列腺癌内分泌治疗所致骨丢失。
- FRAX指导激素受体阳性早期乳腺癌和非转移性前列腺癌患者的骨质疏松治疗。
- 特定高风险患者骨改良药物启动T值应高于FRAX推荐阈值。
核心结论
- 风险分层识别脆弱患者、选择适当序贯治疗并密切监测骨丢失风险患者,可能降低癌症治疗所致骨丢失相关死亡率、发病率及医疗费用。
研究设计与样本
- 叙述性综述,使用预设检索词检索PubMed、MEDLINE和Google Scholar中关于激素受体阳性乳腺癌和非转移性前列腺癌患者癌症治疗所致骨丢失的研究。
- 纳入随机临床试验、Meta分析、循证综述、观察性研究和临床实践指南。
主要发现
- 激素受体阳性早期乳腺癌和非转移性前列腺癌接受内分泌治疗患者的脆性骨折危险因素、筛查策略、最佳治疗时机、给药剂量与疗程及治疗后监测尚未明确定义。
- 骨改良药物(口服和静脉双膦酸盐、地舒单抗)用于治疗激素受体阳性早期乳腺癌和非转移性前列腺癌内分泌治疗所致骨丢失。
- 由于癌症患者骨质疏松管理数据有限,采用与骨质疏松相似的给药方案被认为是合适的。
关键数值与推荐
- FRAX骨折风险评估工具指导激素受体阳性早期乳腺癌和非转移性前列腺癌患者的骨质疏松治疗。
- 对于化疗诱导卵巢衰竭、卵巢切除术和促性腺激素释放激素治疗的绝经前激素受体阳性乳腺癌患者,以及接受芳香化酶抑制剂治疗的绝经后激素受体阳性乳腺癌患者和接受雄激素剥夺治疗的非转移性前列腺癌患者,预防骨丢失的骨改良药物应在高于FRAX推荐阈值的T值启动。
- 骨合成代谢药物一线序贯治疗可能为高即刻骨折风险患者提供潜在治疗策略。
临床怎么用
- 原文未据此给出推荐。
局限性
- 激素受体阳性早期乳腺癌和非转移性前列腺癌接受内分泌治疗患者的脆性骨折危险因素、筛查策略、最佳治疗时机、给药剂量与疗程及治疗后监测尚未明确定义。
- 癌症患者骨质疏松管理数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone modifying agents BMAs (oral and IV bisphosphonates, denosumab) are used to treat bone loss due to endocrine therapy in patients with hormone receptor positive (HR +) early breast cancer and non-metastatic prostate cancer (NMPC). Timely initiation of appropriate sequential therapy is imperative to reduce cancer treatment-induced bone loss (CTIBL). This narrative review summarizes current literature regarding management of CTIBL in HR + early breast cancer and NMPC patients. Risk factors for fragility fractures, screening strategies, optimal timing for the treatment, dosing/duration of therapy, and post treatment monitoring have not been clearly defined in HR + early breast and NMPC patients receiving endocrine therapy. This review aims to discuss the utility of fracture risk assessment (FRAX) tool for the prevention and management of CTIBL, osteoanabolic therapy for imminent fracture risk reduction, and sequential therapy options. Using predefined terms, PubMed, MEDLINE, and Google Scholar were searched for studies on CTIBL in HR + breast and NMPC patients. We included randomized clinical trials, meta-analysis, evidence-based reviews, observational studies, and clinical practice guidelines. Fracture risk assessment tools (FRAX) guide therapy for osteoporosis in patients with early HR + breast cancer and NMPC. BMAs to prevent bone loss should be initiated at higher T-score than recommended by FRAX in premenopausal HR + breast cancer patients with chemotherapy-induced ovarian failure, oophorectomy and gonadotropin releasing hormone (GnRH) therapy, post-menopausal women with HR + breast cancer receiving aromatase inhibitor therapy, and NMPC patients with androgen deprivation therapy. Sequential therapy with osteoanabolic agents as first line treatment offers a potential therapeutic strategy in patients with high imminent fracture risk. Due to limited data in cancer patients regarding management of osteoporosis, a dosing schedule similar to osteoporosis is considered appropriate. Risk stratification to identify vulnerable patient population, choosing the appropriate sequential therapy, and close monitoring of patients at the risk of bone loss can potentially reduce the mortality, morbidity, and health care cost related to CTIBL.
引用
- Khan MI. Management of bone loss due to endocrine therapy during cancer treatment. Osteoporos Int. 2023. PMID: 36656338. doi:10.1007/s00198-023-06672-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。